{"id":23203,"date":"2024-05-29T19:47:27","date_gmt":"2024-05-29T14:17:27","guid":{"rendered":"https:\/\/johnsonfrancis.org\/general\/?p=23203"},"modified":"2024-06-14T20:41:15","modified_gmt":"2024-06-14T15:11:15","slug":"semaglutide-for-heart-failure-with-preserved-ejection-fraction-and-obesity","status":"publish","type":"post","link":"https:\/\/johnsonfrancis.org\/general\/semaglutide-for-heart-failure-with-preserved-ejection-fraction-and-obesity\/","title":{"rendered":"Semaglutide for Heart Failure with Preserved Ejection Fraction and Obesity"},"content":{"rendered":"<p><iframe loading=\"lazy\" width=\"560\" height=\"315\" src=\"https:\/\/www.youtube.com\/embed\/nGa4CLfHAU4?si=gN8cNnWSqBFaJhwm\" title=\"YouTube video player\" frameborder=\"0\" allow=\"accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share\" referrerpolicy=\"strict-origin-when-cross-origin\" allowfullscreen><\/iframe><br \/>\nSemaglutide is a glucagon-like peptide-1 receptor agonist which has been shown to reduce body weight and improve health status in patients with obesity related heart failure with preserved ejection fraction in the STEP-HFpEF Program [1]. Semaglutide was adminstered once weekly as subcutaneous injection. The medication has been approved for long term weight management and has been shown to produce major weight loss in overweight and obese persons. It has favourable effects on cardiometabolic risk. Semaglutide reduces C-Reactive Protein level, systolic blood pressure and NT-proBNP level in patients with obesity and heart failure with preserved ejection fraction.<\/p>\n<p><span style=\"color: #0000ff;\"><strong>Reference<\/strong><\/span><\/p>\n<ol>\n<li>Kosiborod MN, Abildstr\u00f8m SZ, Borlaug BA, Butler J, Rasmussen S, Davies M, Hovingh GK, Kitzman DW, Lindegaard ML, M\u00f8ller DV, Shah SJ, Treppendahl MB, Verma S, Abhayaratna W, Ahmed FZ, Chopra V, Ezekowitz J, Fu M, Ito H, Lelonek M, Melenovsky V, Merkely B, N\u00fa\u00f1ez J, Perna E, Schou M, Senni M, Sharma K, Van der Meer P, von Lewinski D, Wolf D, Petrie MC; STEP-HFpEF Trial Committees and Investigators. <a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/37622681\/\">Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity<\/a>. N Engl J Med. 2023 Sep 21;389(12):1069-1084. doi: 10.1056\/NEJMoa2306963. Epub 2023 Aug 25. PMID: 37622681.<\/li>\n<\/ol>\n","protected":false},"excerpt":{"rendered":"<p>Semaglutide is a glucagon-like peptide-1 receptor agonist which has been shown to reduce body weight and improve health status in patients with obesity related heart failure with preserved ejection fraction in the STEP-HFpEF Program [1]. Semaglutide was adminstered once weekly as subcutaneous injection. The medication has been approved for long term weight management and has [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":23204,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"nf_dc_page":"","footnotes":""},"categories":[7],"tags":[],"class_list":["post-23203","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-general"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.9 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Semaglutide for Heart Failure with Preserved Ejection Fraction and Obesity - All About Heart And Blood Vessels<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/johnsonfrancis.org\/general\/semaglutide-for-heart-failure-with-preserved-ejection-fraction-and-obesity\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Semaglutide for Heart Failure with Preserved Ejection Fraction and Obesity - All About Heart And Blood Vessels\" \/>\n<meta property=\"og:description\" content=\"Semaglutide is a glucagon-like peptide-1 receptor agonist which has been shown to reduce body weight and improve health status in patients with obesity related heart failure with preserved ejection fraction in the STEP-HFpEF Program [1]. Semaglutide was adminstered once weekly as subcutaneous injection. The medication has been approved for long term weight management and has [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/johnsonfrancis.org\/general\/semaglutide-for-heart-failure-with-preserved-ejection-fraction-and-obesity\/\" \/>\n<meta property=\"og:site_name\" content=\"All About Heart And Blood Vessels\" \/>\n<meta property=\"article:published_time\" content=\"2024-05-29T14:17:27+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-06-14T15:11:15+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/johnsonfrancis.org\/general\/wp-content\/uploads\/2024\/05\/Semaglutide-for-Heart-Failure-with-Preserved-Ejection-Fraction-and-Obesity.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1203\" \/>\n\t<meta property=\"og:image:height\" content=\"675\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Johnson Francis\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Johnson Francis\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/general\\\/semaglutide-for-heart-failure-with-preserved-ejection-fraction-and-obesity\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/general\\\/semaglutide-for-heart-failure-with-preserved-ejection-fraction-and-obesity\\\/\"},\"author\":{\"name\":\"Johnson Francis\",\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/general\\\/#\\\/schema\\\/person\\\/f35ea33ecf9c9923597de2691ebed1a7\"},\"headline\":\"Semaglutide for Heart Failure with Preserved Ejection Fraction and Obesity\",\"datePublished\":\"2024-05-29T14:17:27+00:00\",\"dateModified\":\"2024-06-14T15:11:15+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/general\\\/semaglutide-for-heart-failure-with-preserved-ejection-fraction-and-obesity\\\/\"},\"wordCount\":202,\"commentCount\":0,\"image\":{\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/general\\\/semaglutide-for-heart-failure-with-preserved-ejection-fraction-and-obesity\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/johnsonfrancis.org\\\/general\\\/wp-content\\\/uploads\\\/2024\\\/05\\\/Semaglutide-for-Heart-Failure-with-Preserved-Ejection-Fraction-and-Obesity.jpg\",\"articleSection\":[\"General\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/johnsonfrancis.org\\\/general\\\/semaglutide-for-heart-failure-with-preserved-ejection-fraction-and-obesity\\\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/general\\\/semaglutide-for-heart-failure-with-preserved-ejection-fraction-and-obesity\\\/\",\"url\":\"https:\\\/\\\/johnsonfrancis.org\\\/general\\\/semaglutide-for-heart-failure-with-preserved-ejection-fraction-and-obesity\\\/\",\"name\":\"Semaglutide for Heart Failure with Preserved Ejection Fraction and Obesity - All About Heart And Blood Vessels\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/general\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/general\\\/semaglutide-for-heart-failure-with-preserved-ejection-fraction-and-obesity\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/general\\\/semaglutide-for-heart-failure-with-preserved-ejection-fraction-and-obesity\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/johnsonfrancis.org\\\/general\\\/wp-content\\\/uploads\\\/2024\\\/05\\\/Semaglutide-for-Heart-Failure-with-Preserved-Ejection-Fraction-and-Obesity.jpg\",\"datePublished\":\"2024-05-29T14:17:27+00:00\",\"dateModified\":\"2024-06-14T15:11:15+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/general\\\/#\\\/schema\\\/person\\\/f35ea33ecf9c9923597de2691ebed1a7\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/general\\\/semaglutide-for-heart-failure-with-preserved-ejection-fraction-and-obesity\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/johnsonfrancis.org\\\/general\\\/semaglutide-for-heart-failure-with-preserved-ejection-fraction-and-obesity\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/general\\\/semaglutide-for-heart-failure-with-preserved-ejection-fraction-and-obesity\\\/#primaryimage\",\"url\":\"https:\\\/\\\/johnsonfrancis.org\\\/general\\\/wp-content\\\/uploads\\\/2024\\\/05\\\/Semaglutide-for-Heart-Failure-with-Preserved-Ejection-Fraction-and-Obesity.jpg\",\"contentUrl\":\"https:\\\/\\\/johnsonfrancis.org\\\/general\\\/wp-content\\\/uploads\\\/2024\\\/05\\\/Semaglutide-for-Heart-Failure-with-Preserved-Ejection-Fraction-and-Obesity.jpg\",\"width\":1203,\"height\":675},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/general\\\/semaglutide-for-heart-failure-with-preserved-ejection-fraction-and-obesity\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/johnsonfrancis.org\\\/general\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Semaglutide for Heart Failure with Preserved Ejection Fraction and Obesity\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/general\\\/#website\",\"url\":\"https:\\\/\\\/johnsonfrancis.org\\\/general\\\/\",\"name\":\"All About Heart And Blood Vessels\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/johnsonfrancis.org\\\/general\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/general\\\/#\\\/schema\\\/person\\\/f35ea33ecf9c9923597de2691ebed1a7\",\"name\":\"Johnson Francis\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/80861b82c3f559be9e413245c5643b6c483c93495507facfe32cf96ccd8bcffd?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/80861b82c3f559be9e413245c5643b6c483c93495507facfe32cf96ccd8bcffd?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/80861b82c3f559be9e413245c5643b6c483c93495507facfe32cf96ccd8bcffd?s=96&d=mm&r=g\",\"caption\":\"Johnson Francis\"},\"description\":\"Former Professor of Cardiology, Calicut Govt. Medical Kozhikode, Kerala, India. Editor-in-Chief, BMH Medical Journal\",\"url\":\"https:\\\/\\\/johnsonfrancis.org\\\/general\\\/author\\\/jf\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Semaglutide for Heart Failure with Preserved Ejection Fraction and Obesity - All About Heart And Blood Vessels","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/johnsonfrancis.org\/general\/semaglutide-for-heart-failure-with-preserved-ejection-fraction-and-obesity\/","og_locale":"en_US","og_type":"article","og_title":"Semaglutide for Heart Failure with Preserved Ejection Fraction and Obesity - All About Heart And Blood Vessels","og_description":"Semaglutide is a glucagon-like peptide-1 receptor agonist which has been shown to reduce body weight and improve health status in patients with obesity related heart failure with preserved ejection fraction in the STEP-HFpEF Program [1]. Semaglutide was adminstered once weekly as subcutaneous injection. The medication has been approved for long term weight management and has [&hellip;]","og_url":"https:\/\/johnsonfrancis.org\/general\/semaglutide-for-heart-failure-with-preserved-ejection-fraction-and-obesity\/","og_site_name":"All About Heart And Blood Vessels","article_published_time":"2024-05-29T14:17:27+00:00","article_modified_time":"2024-06-14T15:11:15+00:00","og_image":[{"width":1203,"height":675,"url":"https:\/\/johnsonfrancis.org\/general\/wp-content\/uploads\/2024\/05\/Semaglutide-for-Heart-Failure-with-Preserved-Ejection-Fraction-and-Obesity.jpg","type":"image\/jpeg"}],"author":"Johnson Francis","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Johnson Francis","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/johnsonfrancis.org\/general\/semaglutide-for-heart-failure-with-preserved-ejection-fraction-and-obesity\/#article","isPartOf":{"@id":"https:\/\/johnsonfrancis.org\/general\/semaglutide-for-heart-failure-with-preserved-ejection-fraction-and-obesity\/"},"author":{"name":"Johnson Francis","@id":"https:\/\/johnsonfrancis.org\/general\/#\/schema\/person\/f35ea33ecf9c9923597de2691ebed1a7"},"headline":"Semaglutide for Heart Failure with Preserved Ejection Fraction and Obesity","datePublished":"2024-05-29T14:17:27+00:00","dateModified":"2024-06-14T15:11:15+00:00","mainEntityOfPage":{"@id":"https:\/\/johnsonfrancis.org\/general\/semaglutide-for-heart-failure-with-preserved-ejection-fraction-and-obesity\/"},"wordCount":202,"commentCount":0,"image":{"@id":"https:\/\/johnsonfrancis.org\/general\/semaglutide-for-heart-failure-with-preserved-ejection-fraction-and-obesity\/#primaryimage"},"thumbnailUrl":"https:\/\/johnsonfrancis.org\/general\/wp-content\/uploads\/2024\/05\/Semaglutide-for-Heart-Failure-with-Preserved-Ejection-Fraction-and-Obesity.jpg","articleSection":["General"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/johnsonfrancis.org\/general\/semaglutide-for-heart-failure-with-preserved-ejection-fraction-and-obesity\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/johnsonfrancis.org\/general\/semaglutide-for-heart-failure-with-preserved-ejection-fraction-and-obesity\/","url":"https:\/\/johnsonfrancis.org\/general\/semaglutide-for-heart-failure-with-preserved-ejection-fraction-and-obesity\/","name":"Semaglutide for Heart Failure with Preserved Ejection Fraction and Obesity - All About Heart And Blood Vessels","isPartOf":{"@id":"https:\/\/johnsonfrancis.org\/general\/#website"},"primaryImageOfPage":{"@id":"https:\/\/johnsonfrancis.org\/general\/semaglutide-for-heart-failure-with-preserved-ejection-fraction-and-obesity\/#primaryimage"},"image":{"@id":"https:\/\/johnsonfrancis.org\/general\/semaglutide-for-heart-failure-with-preserved-ejection-fraction-and-obesity\/#primaryimage"},"thumbnailUrl":"https:\/\/johnsonfrancis.org\/general\/wp-content\/uploads\/2024\/05\/Semaglutide-for-Heart-Failure-with-Preserved-Ejection-Fraction-and-Obesity.jpg","datePublished":"2024-05-29T14:17:27+00:00","dateModified":"2024-06-14T15:11:15+00:00","author":{"@id":"https:\/\/johnsonfrancis.org\/general\/#\/schema\/person\/f35ea33ecf9c9923597de2691ebed1a7"},"breadcrumb":{"@id":"https:\/\/johnsonfrancis.org\/general\/semaglutide-for-heart-failure-with-preserved-ejection-fraction-and-obesity\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/johnsonfrancis.org\/general\/semaglutide-for-heart-failure-with-preserved-ejection-fraction-and-obesity\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/johnsonfrancis.org\/general\/semaglutide-for-heart-failure-with-preserved-ejection-fraction-and-obesity\/#primaryimage","url":"https:\/\/johnsonfrancis.org\/general\/wp-content\/uploads\/2024\/05\/Semaglutide-for-Heart-Failure-with-Preserved-Ejection-Fraction-and-Obesity.jpg","contentUrl":"https:\/\/johnsonfrancis.org\/general\/wp-content\/uploads\/2024\/05\/Semaglutide-for-Heart-Failure-with-Preserved-Ejection-Fraction-and-Obesity.jpg","width":1203,"height":675},{"@type":"BreadcrumbList","@id":"https:\/\/johnsonfrancis.org\/general\/semaglutide-for-heart-failure-with-preserved-ejection-fraction-and-obesity\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/johnsonfrancis.org\/general\/"},{"@type":"ListItem","position":2,"name":"Semaglutide for Heart Failure with Preserved Ejection Fraction and Obesity"}]},{"@type":"WebSite","@id":"https:\/\/johnsonfrancis.org\/general\/#website","url":"https:\/\/johnsonfrancis.org\/general\/","name":"All About Heart And Blood Vessels","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/johnsonfrancis.org\/general\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/johnsonfrancis.org\/general\/#\/schema\/person\/f35ea33ecf9c9923597de2691ebed1a7","name":"Johnson Francis","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/80861b82c3f559be9e413245c5643b6c483c93495507facfe32cf96ccd8bcffd?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/80861b82c3f559be9e413245c5643b6c483c93495507facfe32cf96ccd8bcffd?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/80861b82c3f559be9e413245c5643b6c483c93495507facfe32cf96ccd8bcffd?s=96&d=mm&r=g","caption":"Johnson Francis"},"description":"Former Professor of Cardiology, Calicut Govt. Medical Kozhikode, Kerala, India. Editor-in-Chief, BMH Medical Journal","url":"https:\/\/johnsonfrancis.org\/general\/author\/jf\/"}]}},"amp_enabled":true,"_links":{"self":[{"href":"https:\/\/johnsonfrancis.org\/general\/wp-json\/wp\/v2\/posts\/23203","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/johnsonfrancis.org\/general\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/johnsonfrancis.org\/general\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/johnsonfrancis.org\/general\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/johnsonfrancis.org\/general\/wp-json\/wp\/v2\/comments?post=23203"}],"version-history":[{"count":5,"href":"https:\/\/johnsonfrancis.org\/general\/wp-json\/wp\/v2\/posts\/23203\/revisions"}],"predecessor-version":[{"id":23213,"href":"https:\/\/johnsonfrancis.org\/general\/wp-json\/wp\/v2\/posts\/23203\/revisions\/23213"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/johnsonfrancis.org\/general\/wp-json\/wp\/v2\/media\/23204"}],"wp:attachment":[{"href":"https:\/\/johnsonfrancis.org\/general\/wp-json\/wp\/v2\/media?parent=23203"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/johnsonfrancis.org\/general\/wp-json\/wp\/v2\/categories?post=23203"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/johnsonfrancis.org\/general\/wp-json\/wp\/v2\/tags?post=23203"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}